RenasantBio
$55.5Mtotal raised · 2 rounds on record
$30Mlatest round · Venture round · Jun 2025 · 17 mo ago
2backers · Atlas Venture, OrbiMed
20team · US Form 5500 (plan participants) · Dec 2025 · +100% in a year
Overview
Correctors and Potentiators for Autosomal Dominant Polycystic Kidney Disease (ADPKD). Transforming the Treatment of ADPKD.
Funding and backers
Total raised
$55.5M
2 rounds on record
Latest round
$30M
Venture round · Jun 2025 · 17 mo ago
Team
20
US Form 5500 (plan participants) · Dec 2025 · +100% in a year
Backers
2
Atlas Venture, OrbiMed
The money's age
Due for its next round
17 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2025
Team of 20 was 10 · US Form 5500 (plan participants)
Jun 3, 2025
Raised a round Venture round $30M · SEC Form D
Jul 15, 2024
Raised a round Venture round $25.5M · SEC Form D
2022
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jun 2025 | $30M | — | SEC Form D |
| Venture round | Jul 2024 | $25.5M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Renasant Bio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Thomas GustafsonExecutive OfficerSEC Form D
Emily ConleyExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Strive Health, Cardurion
Similar startupsby what they do, their industry and backers
AI-Powered Support for Chronic Kidney Disease Care.
Matchpoint aims to discover and develop precision small molecules that harness the power of covalency to bring new possibilities to the…
Somatus is a leader in value-based kidney care working alongside health plans and providers to help prevent the progression of kidney…
Highlights. Vincere makes new medicines to treat age-related diseases including Parkinson's and Kidney disease.
Kalium Health | Precision testing to transform the management of chronic kidney disease and heart disease.
Creating innovative therapies for chronic kidney disease patients. Addressing left ventricular hypertrophy with monoclonal antibody…
People
Thomas Gustafson
Executive Officer
Emily Conley
Executive Officer, Director
Evan Caplan
Director
Natalie Holles
Director
Charlotte McKee
Director
Deborah Palestrant
Director
Anna French
Director
Kevin Bitterman
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Atlas VentureVia a fund
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Renasant Bio, an underdog in the race to develop kidney disease therapies, raises $54.5 million
The company plans to develop two therapies for a common renal condition called autosomal dominant polycystic kidney disease, or ADPKD.
Read more
Report
Renasant Bio debuts with sights on root causes of polycystic kidney disease (FirstWord Pharma)
Read more
Report
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Berkeley
United States
HQ
50-200 est. staff